Please use this identifier to cite or link to this item:
|Title:||Alphaknife for glioma tumors: two years experiences with targeted alpha therapy of 213Bi-substance P|
|Authors:||KROLICKI Leszek; MORGENSTERN Alfred; KUNIKOWSKA Jolanta; KOZIARA H; KROLICKI B; JAKUCINSKI M; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank|
|Citation:||EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 41 no. Supplement 2 p. S 291 - Abstract n° OP603|
|Type:||Articles in periodicals and books|
|Abstract:||Glioblastoma multiforme (GBM) is characterized by the worst prognosis with an overall survival (OS) 9-15 months, median 13 months. The infiltrating character of the tumor, molecular heterogeneity, as well as the protective effects of blood-brain barrier are the causes of insufficient front line treatments (surgery, radio and chemotherapy); 90% of patients have a recurrence at the original tumor location. Therefore a new type of strategies must be implemented and proofed. It has been demonstrated that NK-1 receptor system is extensively expressed in glioma cells, and substance P can be used as a ligand for targeted therapy. On the other hand alpha emitter, like 213Bi offers the new potential for selective irradiation of tumors, with minimizing damage to adjacent tissue.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.